PRESS RELEASE FROM Clinical Pharmacology & Therapeutics
(http://www.nature.com/clpt)
For papers that will be published online on 24 June 2009
This press release is copyrighted to the journal Clinical Pharmacology & Therapeutics.
A PDF of the paper mentioned on this release can be found in the Academic journals section of http://press.nature.com. Press contacts for the journals are listed at the end of this release.
Warning: This document, and the Academic Journal paper to which it refers, may contain information that is price sensitive (as legally defined, for example, in the UK Criminal Justice Act 1993 Part V) with respect to publicly quoted companies. Anyone dealing in securities using information contained in this document or in advanced copies of Nature’s content may be guilty of insider trading under the US Securities Exchange Act of 1934.
PICTURES: While we are happy for images from Clinical Pharmacology & Therapeutics to be reproduced for the purposes of contemporaneous news reporting, you must also seek permission from the copyright holder (if named) or author of the research paper in question (if not).
HYPE: We take great care not to hype the papers mentioned on our press releases, but are sometimes accused of doing so. If you ever consider that a story has been hyped, please do not hesitate to contact us at [email protected], citing the specific example.
PLEASE CITE Clinical Pharmacology & Therapeutics AND THE Clinical Pharmacology & Therapeutics WEBSITE AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO www.nature.com/clpt/
Adiponectin: biomarker for diabetes
DOI:10.1038/clpt.2009.88
The metabolic hormone adiponectin could serve as a predictive biomarker for type 2 diabetes (T2D), according to a study published online in this week’s Clinical Pharmacology & Therapeutics. The research may help doctors prescribe better therapies with fewer side effects to the 24 million Americans who suffer from type 2 diabetes.
Adiponectin is a hormone that regulates a number of metabolic processes, such as glucose regulation and the metabolism of fat for energy production. Numerous studies have shown a link between adiponectin and insulin sensitivity but the study from John A. Wagner and colleagues re-affirms that levels of the hormone in T2D patients could also predict how they will respond to certain anti-diabetes drugs.
A group of receptors known as PPARs play an important role in regulating metabolism genes that help cells respond to insulin. Compiling data from patients involved in several different clinical trials, the team showed that levels of adiponectin in the blood are a robust predictor of PPAR activation and subsequent response to insulin. The findings support the possible use of adiponectin as a biomarker to monitor glucose tolerance. The authors also propose that adiponectin could serve as a diagnostic biomarker to predict how patients will respond to thiazolidinediones, a commonly used drug in the treatment to T2D.
This study was conducted by the Metabolic Disorders Steering Committee of the Biomarkers Consortium which is managed by the Foundation for the National Institutes of Health. The committee, comprised of government, industry and non-profit partners, used blinded data from four pharmaceutical companies that had conducted separate clinical trials with PPAR targeting and non-PPAR targeting drugs. This process of pooling data may ultimately lead to reduced research and development costs and improved patient care.
Author contact:
John A. Wagner (Merck Research Laboratories, Rahway, New Jersey, USA)
Te: +1 732 594 0274; E-mail: [email protected]
Editorial contact:
Joyce-Rachel John (Senior Publishing Manager, Clinical Pharmacology & Therapeutics, New York, NY, USA)
Tel: +1 212 726 9214; E-mail: [email protected]
PRESS CONTACTS
For media inquiries relating to embargo policy for the Clinical Pharmacology & Therapeutics:
Neda Afsarmanesh (Nature New York)
Tel: +1 212 726 9231; E-mail: [email protected]
Ruth Francis (Nature London)
Tel: +44 20 7843 4562; E-mail: [email protected]
About Nature Publishing Group (NPG)
Nature Publishing Group is a division of Macmillan Publishers Ltd, dedicated to serving the academic and professional scientific and medical communities. NPG’s flagship title, Nature, was first published in 1869. Other publications include Nature research journals, Nature Reviews, Nature Clinical Practice and a range of prestigious academic journals including society-owned publications. NPG also provides news content through Nature News. Scientific career information and free job postings are offered on Naturejobs.
NPG is a global company with principal offices in London and New York and offices in Basingstoke, Boston, Buenos Aires, Delhi, Hong Kong, Madrid, Melbourne, Munich, Paris, San Francisco, Tokyo and Washington DC. For more information, please go to www.nature.com.
